Vanguard Group Inc Moon Lake Immunotherapeutics Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
A detailed history of Vanguard Group Inc transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Vanguard Group Inc holds 92,298 shares of MLTX stock, worth $4.06 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
92,298
Previous 73,657
25.31%
Holding current value
$4.06 Million
Previous $4.45 Million
4.23%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding MLTX
# of Institutions
135Shares Held
56MCall Options Held
379KPut Options Held
402K-
Bvf Inc San Francisco, CA21.8MShares$956 Million32.73% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$373 Million24.56% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.58MShares$113 Million1.56% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.31MShares$102 Million0.02% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.28MShares$100 Million0.23% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.62B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...